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Abstract 
A possible increased risk of nephrotic syndrome (NS) following a meningococal group B 
vaccination campaign was identified during active safety surveillance in a province in 
Quebec, Canada where 4 cases were reported from an exposed population of ~ 49,0000, a 
higher rate than in provinces not using the vaccine. Meningococcal B vaccine has been given 
routinely at 2, 4 and 12 months of age in the United Kingdom since September 2015. To 
investigate the Canadian signal we used English hospital admissions data from 2005 to 2019 
in 2-23 month old children to determine whether the rate of NS changed following the 
introduction of the vaccine. The analysis was stratified by age 2-5 months, 6-11 months, 12-
17 months and 18-23 months. The results showed no evidence of an increased risk with 
incidence rate ratios between 0.81 (95% confidence interval 0.56-1.19) for age 6-11 months 
and 1.18 (0.84-1.66) for age 12-17 months.  
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Introduction  
The multicomponent group B meningococcal vaccine (4CMenB, Bexsero GSK, Rixensart, 
Belgium) was introduced in the United Kingdom (UK) in September 2015 as a 2,4,12 month 
(2+1) schedule [1]. All birth cohorts from May 2015 were eligible with the first booster doses 
given from May 2016 as the first vaccine-eligible cohort reached 12 months of age.  Vaccine 
uptake rapidly reached high levels with over 95% receiving the first dose and 87% 2+1 doses. 
[2] By 2018 the vaccine had a clear impact on meningococcal group B disease in the target 
ages in England with a 75% reduction compared to the expected incidence and with vaccine 
effectiveness of about 60% for the 2+1 schedule. [2]  
In clinical trials 4CMenB was found to be fairly reactogenic with fever within 6 hours of 
vaccination frequently reported [3] which was reduced by 40-50% if prophylactic 
paracetamol was given [4]. In Canada 4CMenB was used in a campaign beginning in May 
2014 for children aged 2 months to 20 years in a region of Quebec where the incidence of 
meningococcal group B disease was high. Active post-vaccination safety follow-up was 
conducted by an online questionnaire. [5] The vaccine was given as four doses in infants 
under 6 months, three doses in older infants or two doses in those aged 1-20 years. The active 
surveillance produced a signal of a possible increased risk of nephrotic syndrome (NS), a 
renal disorder resulting in loss of albumen in the urine with generalised oedema in which 
relapse frequently occurs. Three cases of NS were identified by the active surveillance and an 
additional case found in a hospital database search. The cases occurred within 6 months of 
vaccination in children aged 2-5 years with the diagnoses made after a second dose (although 
two had symptoms prior to the second dose) and all were first episodes. Three cases were 
hospitalised giving a rate of 13.3 cases per 100,000 vaccinated individuals which was 3.6 fold 
(95% CI 0.7-11.8) higher than in the rest of the province where the vaccine was not given, 
and 8.3 fold higher (95% CI: 1.1-62.0) higher than the rate in an 8 year pre-vaccination 
period.  
An increased risk of NS has not been reported after other vaccines although a signal of an 
increased risk of NS relapse was raised with meningococcal C conjugate vaccine [6]. 
However, a subsequent analytic epidemiological study found no evidence of an increased risk 
of NS relapse after the vaccine [7]. Given the signal from 4CMenB in Canada, and the 
extensive use of the vaccine in the UK, we conducted an ecological study to assess whether 
rates of NS changed following the mass introduction of the vaccine. Although the age range 
for 4CMenB in the UK is lower than that of the cases seen in Canada the large-scale use 
warrants the assessment of the NS signal. The high vaccine uptake and stable incidence of NS 
prior to vaccine introduction made an ecological study a feasible method to investigate the 
Canadian signal. 
Methods 
The Hospital Episodes Statistics (HES) dataset holds information on all hospital admissions 
to a National Health Service Hospital in England [8] and was used to identify NS cases.  
Admissions with a diagnosis of nephrotic syndrome (ICD codes of N040 or N049) in the first 
diagnostic field were extracted for the period September 2005 to April 2019 for children aged 
2-23 months of age. Any episode within 7 days of a previous episode was assumed to be part 
of the same episode. Episodes more than 7 days after a previous episode were assumed to be 
relapses. When assessing first episodes, to ensure all episodes were the first,  only cases from 
September 2006-April 2019 were used for those aged 2-11 months and September 2007-April 
2019 for those aged 12-23 months. Counts of cases were aggregated by the admission month 
and year and by the age of the case, and each of these cohorts assigned as vaccine eligible or 
not based on the corresponding birth cohort. Population data for England from 2005-2017 
was obtained from the Office of National Statistics (ONS) to calculate person-time spent in 
each of these cohorts (population for 2018 was assumed to be the same as 2017) [9].  For 
descriptive analyses, counts and person time were then aggregated across age ranges of 2-5 
months, 6-11 months, 12-17 months and 18-23 months as well as by year (September to 
August). Case numbers in each year were corrected to the 2017 population denominator for 
presentation. This meant for 2018/19 case numbers were inflated to the expected number 
from a full year’s follow-up rather than September -March.  To compare the incidence before 
and after vaccination introduction, rates were calculated per 100,000 person years within the 
age groups and according to whether eligible for vaccination. Poisson regression was used to 
estimate the incidence rate ratio (IRR) in the vaccine eligible compared to non-eligible 
cohorts after checking for any secular trends. Analyses were done based on first episodes as 
well as using all episodes. Estimation of doses given to the population was from data on 
population coverage in the UK as used in the assessment of the impact of Meningococcal B 
vaccination. [2] 
Results 
A total of 876 episodes were obtained for 2005/06 to 2018/19 after removing those within 7 
days.  Of these, 328 were the first recorded admission in the period of which 9 were dropped 
in under one year olds for 2005/06 and 51 in one year olds for 2005-2007, as an earlier 
admission prior to these dates could not be excluded. Figures 1 and 2 show the adjusted 
counts over the period, with no evidence of an increase following the introduction of 
4CMenB vaccination. NS admissions increased with age with the largest number of cases in 
the 18-23 month group. There was no evidence of an increasing trend in NS over time so 
unadjusted IRRs could be calculated. Tables 1 and 2 show the cases, person-time and 
incidence in the vaccine eligible and non-eligible periods by age group. The IRRs comparing 
vaccine eligible with non-eligible cohorts ranged from 0.81 to 1.18 with all 95% confidence 
intervals including one and the highest upper limit being 2.67.  
Discussion 
In this follow-up period about 44 monthly birth cohorts were eligible for the first dose, 45 
cohorts for the second and 34 for the booster dose of 4CMenB. Based on vaccine coverage 
estimates of about 95% for the first dose, 93% for the second dose and 87% for the third dose 
[2] and an English birth cohort of about 55,000 per month this gives a total exposure of about 
2.35 million first doses, 2.25 million second doses and 1.78 million booster doses. With this 
large number of doses administered in the period covered by this study it would be expected 
that an increased risk of NS of the size signalled in Canada, if it existed, would be detected. 
For example, if it is assumed that the risk is for at least 4-5 months post-vaccination, as 
suggested by the Canadian study, then in the vaccine eligible period much of the person-time 
in those aged 2-5 as well as 12-17 months will be post-vaccination risk time. If we assume 
about 80% of the 2-5 month age group person time will be in the risk period (to allow for 
some delayed vaccination and 5% unvaccinated) then to generate the observed upper end of 
the 95% CI for the IRR of 1.58 (for the cases including relapses) the true IRR would need to 
be 1.73 (1.73×0.8 + 1.00×0.2 = 1.58). Similarly, if we assume about 65% of the 12-17 month 
age period is risk (to allow for 80% coverage and some delayed vaccination) then to generate 
a IRR of 1.66 then the actual RI would need to be 2.0 (2.00×0.65 + 1.00×0.35 = 1.66).  
Similar calculations based on first episodes (where upper 95% CI IRRs were 2.14 and 1.91) 
would require the actual IRRs to be 2.43 for age 2-5 months and 2.40 for age 12-17 months.  
This study has the usual limitations of an ecological study, with individual vaccination 
history not ascertained and inferences made about risk in individual vaccinees based on 
population aggregated data.  However, with the high 4CMenB coverage levels in England a 
large increased risk should have been clear in these data.  As shown by the above 
calculations, an increased risk of more than double after 4CMenB can be confidently 
excluded. While extraneous factors causing a reduction in NS incidence that happened to 
coincide with 4CMenB introduction could potentially have obscured a vaccine-associated 
risk, this seems unlikely given the stable incidence of NS over a long period prior to 4CMenB 
introduction. We also did not validate the NS cases by case note review. However, we did do 
case note reviews in our earlier HES based study of meningococcal C vaccine in which we 
used the same ICD codes to identify NS cases [7]. This showed that 53/64 (83%) were 
confirmed demonstrating a high positive predictive value (PPV), although any PPV less than 
100% would further slightly dilute a true risk. The study also does not address vaccination 
across a wide age range as in Canada for which the NS cases were in children vaccinated age 
2-5 years, but does apply to the schedule as used in the UK with a much larger exposed 
population. 
This ecological study therefore provides no evidence of an increased risk of NS after 
introduction of 4CMenB and provides evidence against IRRs of the size given as the point 
estimates in the study from Canada of 3.6-8.3. 
 
Table 1: Comparison of the rate of nephrotic syndrome first episodes in the pre and 
post 4CMenB vaccination periods by age group. 
  Age of cases 




Cases 27 19 41 122 




1.34 0.60  1.37 3.87 
Vaccine 
eligible 
Cases 11 7 12 29 




1.43  0.68  1.38  4.13 
















Table 2: Comparison of the rate of nephrotic syndrome  episodes including relapses  in 
the pre and post 4CMenB vaccination periods by age group. 
  Age of cases 




Cases 92 136 151 331 




4.15 3.94 4.18 8.75 
Vaccine 
eligible 
Cases 34 33 43 56 




4.41  3.20 4.95 7.97 
 Incidence rate 














Figure1: Nephrotic syndrome first episode hospital admissions 2006/07-2018/19 by age 
group. Black bars indicate non-4CMenB eligible cohorts, dark grey partially eligible and light 
grey fully eligible. Case counts are corrected to the 2017/18 population denominator. 
 
Figure 2: Nephrotic syndrome hospital admissions 2005/06-2018/19 by age group including 
relapses. Black bars indicate non-4CMenB eligible cohorts, dark grey partially eligible and 
light grey fully eligible. Case counts are corrected to the 2017/18 population denominator. 
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